Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

222 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update.
Van Poznak C, Somerfield MR, Barlow WE, Biermann JS, Bosserman LD, Clemons MJ, Dhesy-Thind SK, Dillmon MS, Eisen A, Frank ES, Jagsi R, Jimenez R, Theriault RL, Vandenberg TA, Yee GC, Moy B. Van Poznak C, et al. Among authors: theriault rl. J Clin Oncol. 2017 Dec 10;35(35):3978-3986. doi: 10.1200/JCO.2017.75.4614. Epub 2017 Oct 16. J Clin Oncol. 2017. PMID: 29035643
American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer.
Van Poznak CH, Temin S, Yee GC, Janjan NA, Barlow WE, Biermann JS, Bosserman LD, Geoghegan C, Hillner BE, Theriault RL, Zuckerman DS, Von Roenn JH; American Society of Clinical Oncology. Van Poznak CH, et al. Among authors: theriault rl. J Clin Oncol. 2011 Mar 20;29(9):1221-7. doi: 10.1200/JCO.2010.32.5209. Epub 2011 Feb 22. J Clin Oncol. 2011. PMID: 21343561
Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience.
Wolff AC, Blackford AL, Visvanathan K, Rugo HS, Moy B, Goldstein LJ, Stockerl-Goldstein K, Neumayer L, Langbaum TS, Theriault RL, Hughes ME, Weeks JC, Karp JE. Wolff AC, et al. Among authors: theriault rl. J Clin Oncol. 2015 Feb 1;33(4):340-8. doi: 10.1200/JCO.2013.54.6119. Epub 2014 Dec 22. J Clin Oncol. 2015. PMID: 25534386 Free PMC article.
Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study.
Vaz-Luis I, Ottesen RA, Hughes ME, Mamet R, Burstein HJ, Edge SB, Gonzalez-Angulo AM, Moy B, Rugo HS, Theriault RL, Weeks JC, Winer EP, Lin NU. Vaz-Luis I, et al. Among authors: theriault rl. J Clin Oncol. 2014 Jul 10;32(20):2142-50. doi: 10.1200/JCO.2013.53.1608. Epub 2014 Jun 2. J Clin Oncol. 2014. PMID: 24888816 Free PMC article.
NCCN Task Force Report: Bone Health and Cancer Care.
Theriault RL, Biermann JS, Brown E, Brufsky A, Demers L, Grewal RK, Guise T, Jackson R, McEnery K, Podoloff D, Ravdin P, Shapiro CL, Smith M, Van Poznak CH. Theriault RL, et al. J Natl Compr Canc Netw. 2006 May;4 Suppl 2:S1-20; quiz S21-2. J Natl Compr Canc Netw. 2006. PMID: 16737674
Breast cancer treatment guidelines in older women.
Giordano SH, Hortobagyi GN, Kau SW, Theriault RL, Bondy ML. Giordano SH, et al. Among authors: theriault rl. J Clin Oncol. 2005 Feb 1;23(4):783-91. doi: 10.1200/JCO.2005.04.175. J Clin Oncol. 2005. PMID: 15681522
The role of bisphosphonates in breast cancer.
Theriault RL. Theriault RL. J Natl Compr Canc Netw. 2003 Apr;1(2):232-41. doi: 10.6004/jnccn.2003.0022. J Natl Compr Canc Netw. 2003. PMID: 19768882 Review.
222 results